Literature DB >> 11033517

[Sensitized immunofixation: a new technique for analyzing the oligoclonal pattern of CSF immunoglobulins].

S Desplat1, J Pelletier, J Pouget, F Bellon, D Bernard, J Boucraut.   

Abstract

Intrathecal immunoglobulin synthesis is observed in more than 90% of all cases of multiple sclerosis, producing a specific CSF IgG oligoclonal electrophoretic pattern. The consensual method used as reference is isoelectric focusing (IEF). We developed a new CSF Ig analysis method by immunofixation (IF). The method includes an immunoenzymatic detection step performed directly on the gel allowing the use of unconcentrated CSF and avoiding the blotting step. The reliability of this method was established by the analysis of 210 CSF/serum pairs including defined, probable and possible MS, other inflammatory CNS diseases and controls (noninflammatory CNS diseases and peripheral nervous system diseases). Intrathecal IgG synthesis was detected in 95.5% of defined MS cases. The specificity for CNS inflammatory diseases including MS diagnosis, evaluated by comparison with controls, was 98.8%. This new method is quicker and visual interpretation is easier than with IEF. It is a semi-automated method that should be considered for standardization of CSF IgG analysis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11033517

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  2 in total

1.  Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry.

Authors:  Sophie Desplat-Jégo; Lionel Feuillet; Jean Pelletier; Dominique Bernard; André Ali Chérif; José Boucraut
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

2.  Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid.

Authors:  Norbert W Lutz; Angèle Viola; Irina Malikova; Sylviane Confort-Gouny; Bertrand Audoin; Jean-Philippe Ranjeva; Jean Pelletier; Patrick J Cozzone
Journal:  PLoS One       Date:  2007-07-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.